Microdose: An Introduction to MDMA Therapy
MDMA has been gaining attention for its potential therapeutic applications. In recent years, MDMA therapy, particularly MDMA-assisted psychotherapy, has been a topic of extensive research, with MAPS’ …
MDMA-Assisted Therapy
Mugglehead Magazine: American Medical Association approves medical code for psychedelic therapies coverage
The code was the result of a partnership between U.K.-based COMPASS Pathways and the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation to facilitate access and insurance …
Nature: US could soon approve MDMA therapy — opening an era of psychedelic medicine
Quote Originally appearing here (Archived)
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
Greenmarket Report: Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs
The bill – HD 2137, by state Rep. Nicholas Boldyga – was introduced in January, apparently in response to reporting by The Washington Post and The New York Times regarding moves by the nonprofit …
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Database in Phase 3 Trial of MDMA-Assisted Therapy for PTSD (MAPP2) Locked and Finalized
Since the final participant for this MAPP2 was treated on November 17, 2022, the database has been locked and is being analyzed. This study is our second Phase 3 trial of MDMA-assisted therapy for posttraumatic …
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed (MAPP2)
MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
Now Enrolling: Long-Term Follow Up Study MPLONG
Enrollment continues in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 studies of MDMA-assisted therapy for the treatment of PTSD. You are eligible to participate …
Enrolling: Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
Our Bronx VA study site continues to actively screen for new participants. Enrollment is continuing for this Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with …
Currently Enrolling: Food Effect on Bioavailability of MDMA in Healthy Volunteers Study (MPKF)
In August 2022, the first participant was enrolled and received the study drug in our Phase 1 food effect study. This study is examining the effect of food on the bioavailability of MDMA in healthy volunteers …
100 Volunteers Participate, Enrollment Continues for Long-Term Follow Up Study (MPLONG)
As of September 13, 100 participants have participated in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 MDMA-assisted therapy studies for the treatment of …